Early stage resectable non-small cell lung cancer: is neoadjuvant immunotherapy the right way forward?
作者信息
Chiari Rita, Sidoni Angelo, Metro Giulio
机构信息
Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy.
Section of Anatomic Pathology and Histology, Department of Experimental Medicine, University of Perugia Medical School, Perugia, Italy.
出版信息
J Thorac Dis. 2018 Nov;10(Suppl 33):S3890-S3894. doi: 10.21037/jtd.2018.10.22.
Abstract
摘要
相似文献
1
Early stage resectable non-small cell lung cancer: is neoadjuvant immunotherapy the right way forward?早期可切除非小细胞肺癌：新辅助免疫疗法是正确的前进方向吗？
J Thorac Dis. 2018 Nov;10(Suppl 33):S3890-S3894. doi: 10.21037/jtd.2018.10.22.
2
Immunotherapy in surgically resectable non-small cell lung cancer.可手术切除的非小细胞肺癌的免疫治疗
J Thorac Dis. 2018 Feb;10(Suppl 3):S404-S411. doi: 10.21037/jtd.2017.12.93.
3
Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.帕博利珠单抗新辅助免疫治疗可切除淋巴结阳性 II/IIIa 期非小细胞肺癌（NSCLC）：NEOMUN 试验。
BMC Cancer. 2019 May 2;19(1):413. doi: 10.1186/s12885-019-5624-2.
4
Immunotherapy in patients with early stage resectable nonsmall cell lung cancer.早期可切除非小细胞肺癌患者的免疫治疗。
Curr Opin Oncol. 2019 Jan;31(1):13-17. doi: 10.1097/CCO.0000000000000497.
5
Neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer.可切除非小细胞肺癌患者的新辅助免疫治疗
J Thorac Cardiovasc Surg. 2019 Nov;158(5):1471-1474. doi: 10.1016/j.jtcvs.2019.06.114. Epub 2019 Aug 29.
6
[The outcome and safety of neoadjuvant PD-1 blockade plus chemotherapy in stage Ⅱ~Ⅲ non-small cell lung cancer].Ⅱ~Ⅲ期非小细胞肺癌新辅助PD-1阻断联合化疗的疗效与安全性
Zhonghua Zhong Liu Za Zhi. 2020 Jun 23;42(6):480-485. doi: 10.3760/cma.j.cn112152-20200213-00087.
7
Neoadjuvant Treatments for Advanced Resectable Melanoma.晚期可切除黑色素瘤的新辅助治疗
J Surg Oncol. 2019 Jan;119(2):216-221. doi: 10.1002/jso.25352. Epub 2018 Dec 27.
8
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.可切除非小细胞肺癌患者新辅助阿替利珠单抗和化疗：一项开放标签、多中心、单臂、2 期临床试验。
Lancet Oncol. 2020 Jun;21(6):786-795. doi: 10.1016/S1470-2045(20)30140-6. Epub 2020 May 7.
9
Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).术前 PD1 检查点阻断和核因子κB 受体激活剂配体（RANKL）抑制在非小细胞肺癌（NSCLC）中的药效学：一项多中心、开放标签、1B/2 期、转化试验（POPCORN）的研究方案。
Trials. 2019 Dec 19;20(1):753. doi: 10.1186/s13063-019-3951-x.
10
Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).一项多中心II期研究，评估多西他赛和顺铂作为手术或多西他赛同步放化疗前的新辅助诱导方案，随后对II期、IIIA期和IIIB期非小细胞肺癌初治患者进行辅助多西他赛治疗（TAX-AT 1.203试验）。
Lung Cancer. 2014 Sep;85(3):395-400. doi: 10.1016/j.lungcan.2014.06.019. Epub 2014 Jul 3.
引用本文的文献
1
Real-World Survival Outcomes Based on Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study.基于中国肺腺癌患者完全切除术后突变状态的真实世界生存结局：ICAN研究结果
JTO Clin Res Rep. 2021 Nov 25;3(1):100257. doi: 10.1016/j.jtocrr.2021.100257. eCollection 2022 Jan.
2
New Perspectives in Different Gene Expression Profiles for Early and Locally Advanced Non-Small Cell Lung Cancer Stem Cells.早期和局部晚期非小细胞肺癌干细胞不同基因表达谱的新视角
Front Oncol. 2021 Mar 31;11:613198. doi: 10.3389/fonc.2021.613198. eCollection 2021.
3
The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.新辅助和辅助免疫治疗对胰腺癌患者生存的影响：一项回顾性分析。
BMC Cancer. 2020 Jun 9;20(1):538. doi: 10.1186/s12885-020-07016-8.
4
The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database.免疫疗法对接受胰腺肿瘤根治性手术的胰腺腺癌患者生存的影响：国家癌症数据库的回顾性分析。
Radiat Oncol. 2020 Jun 3;15(1):139. doi: 10.1186/s13014-020-01569-5.
5
Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas .通过DNA电穿孔对ROS1进行免疫可损害K-Ras驱动的肺腺癌。
Vaccines (Basel). 2020 Apr 6;8(2):166. doi: 10.3390/vaccines8020166.
6
Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer-Just About Ready for Prime-Time?用于肺癌分子和免疫分析的多重免疫组织化学——即将迎来黄金时代？
Cancers (Basel). 2019 Feb 27;11(3):283. doi: 10.3390/cancers11030283.
本文引用的文献
1
Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?反对观点：免疫疗法是否应纳入致癌基因驱动的肺癌治疗中？
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S290-S293. doi: 10.21037/tlcr.2018.07.11.
2
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.基于血液的肿瘤突变负担可预测接受阿替利珠单抗治疗的非小细胞肺癌患者的临床获益。
Nat Med. 2018 Sep;24(9):1441-1448. doi: 10.1038/s41591-018-0134-3. Epub 2018 Aug 6.
3
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).癌症免疫治疗学会关于免疫治疗非小细胞肺癌（NSCLC）的共识声明。
J Immunother Cancer. 2018 Jul 17;6(1):75. doi: 10.1186/s40425-018-0382-2.
4
Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.通过 PD-1 抑制进行免疫重编程可提高早期肺癌的生存率。
JCI Insight. 2018 Jul 12;3(13):96836. doi: 10.1172/jci.insight.96836.
5
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.新辅助 PD-1 阻断治疗可切除性肺癌。
N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16.
6
Cancer immunotherapy using checkpoint blockade.使用免疫检查点阻断的癌症免疫疗法。
Science. 2018 Mar 23;359(6382):1350-1355. doi: 10.1126/science.aar4060. Epub 2018 Mar 22.
7
Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.非小细胞肺癌治疗的（变）革：十年进展及未来展望
Ecancermedicalscience. 2017 Nov 30;11:787. doi: 10.3332/ecancer.2017.787. eCollection 2017.
8
Incidence and mortality of lung cancer: global trends and association with socioeconomic status.肺癌的发病率和死亡率：全球趋势及其与社会经济地位的关系。
Sci Rep. 2017 Oct 30;7(1):14300. doi: 10.1038/s41598-017-14513-7.
9
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.高突变循环肿瘤 DNA：与基于检查点抑制剂免疫治疗反应的相关性。
Clin Cancer Res. 2017 Oct 1;23(19):5729-5736. doi: 10.1158/1078-0432.CCR-17-1439.
10
Epidemiology, incidence and mortality of lung cancer and their relationship with the development index in the world.全球肺癌的流行病学、发病率和死亡率及其与发展指数的关系。
J Thorac Dis. 2016 Jun;8(6):1094-102. doi: 10.21037/jtd.2016.03.91.
Zotero 插件